Andrea Márta Fodor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Márta Fodor has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Adina Huțanu
Department of Laboratory Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania
1 shared publication - Ana-Maria Fotache (Țurcan)
Doctoral School of Medicine and Pharmacy (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mure, 540139 Târgu Mureș, Romania
1 shared publication - Andreea Truța
Central Laboratory, Emergency Clinical County Hospital Targu Mureș, 540136 Târgu Mureș, Romania
1 shared publication - Bernadett Csipor
Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureş, 540139 Târgu Mureș, Romania
1 shared publication - Enikő Nemes-Nagy
Department of Chemistry and Medical Biochemistry, Faculty of Medicine in English, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureş, 540139 Târgu Mureș, Romania
1 shared publication - Enikő-Csilla Barabás
Department of Cellular Biology and Microbiology, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania
1 shared publication
Latest Publications
- Open Access
Clinical Reclassification of Vitamin D Status Across Three Automated Immunoassays After Comparability Study
Background/Objectives: Variability between routine laboratory immunoassays for total 25-hydroxyvitamin D (25(OH) vitamin D) measurement may impact clinical interpretation, particularly around clinical decision thresholds. The aim of the study was to evaluate the analytical comparability and clinical interchangeability between three automated immunoassay platforms using chemiluminescent assays (CLIA) and electrochemiluminescent assay (ECLIA) principles for total 25(OH) vitamin D and to evaluate the assay-dependent impact on patient reclassification. Methods: A total of 83 serum samples were analyzed using three automated immunoassay platforms and the between method comparability was assessed. Additionally, clinical agreement and reclassification rate were evaluated at two clinical decision thresholds, 20 ng/mL for insufficiency and 12 ng/mL for severe deficiency. Results: The comparability analysis revealed a systematic difference between methods, with a high reclassification rate between ECLIA compared to CLIA methods. Additionally, the expanded measurement uncertainty generates a clinically relevant gray zone around the clinically relevant thresholds. Conclusions: Routinely used immunoassays for total 25(OH) vitamin D measurement in clinical laboratories are not fully interchangeable, furthermore the measurement uncertainty contributes to patient reclassification, especially around the threshold of 20 ng/mL.
Open AccessClinical Reclassification of Vitamin D Status Across Three Automated Immunoassays After Comparability Study
Background/Objectives: Variability between routine laboratory immunoassays for total 25-hydroxyvitamin D (25(OH) vitamin D) measurement may impact clinical interpretation, particularly around clinical decision thresholds. The aim of the study was to evaluate the analytical comparability and clinical interchangeability between three automated immunoassay platforms using chemiluminescent assays (CLIA) and electrochemiluminescent assay (ECLIA) principles for total 25(OH) vitamin D and to evaluate the assay-dependent impact on patient reclassification. Methods: A total of 83 serum samples were analyzed using three automated immunoassay platforms and the between method comparability was assessed. Additionally, clinical agreement and reclassification rate were evaluated at two clinical decision thresholds, 20 ng/mL for insufficiency and 12 ng/mL for severe deficiency. Results: The comparability analysis revealed a systematic difference between methods, with a high reclassification rate between ECLIA compared to CLIA methods. Additionally, the expanded measurement uncertainty generates a clinically relevant gray zone around the clinically relevant thresholds. Conclusions: Routinely used immunoassays for total 25(OH) vitamin D measurement in clinical laboratories are not fully interchangeable, furthermore the measurement uncertainty contributes to patient reclassification, especially around the threshold of 20 ng/mL.
- Open Access
- 9 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (12) , 6388
Cardiovascular Effects of Herbal Products and Their Interaction with Antihypertensive Drugs—Comprehensive Review
Hypertension is a highly prevalent population-level disease that represents an important risk factor for several cardiovascular complications and occupies a leading position in mortality statistics. Antihypertensive therapy includes a wide variety of drugs. Additionally, the potential antihypertensive and cardioprotective effects of several phytotherapy products have been evaluated, as these could also be a valuable therapeutic option for the prevention, improvement or treatment of hypertension and its complications. The present review includes an evaluation of the cardioprotective and antihypertensive effects of garlic, Aloe vera, green tea, Ginkgo biloba, berberine, ginseng, Nigella sativa, Apium graveolens, thyme, cinnamon and ginger, and their possible interactions with antihypertensive drugs. A literature search was undertaken via the PubMed, Google Scholar, Embase and Cochrane databases. Research articles, systematic reviews and meta-analyses published between 2010 and 2023, in the English, Hungarian, and Romanian languages were selected.
- 9 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (12) , 6388
Open AccessCardiovascular Effects of Herbal Products and Their Interaction with Antihypertensive Drugs—Comprehensive Review
Hypertension is a highly prevalent population-level disease that represents an important risk factor for several cardiovascular complications and occupies a leading position in mortality statistics. Antihypertensive therapy includes a wide variety of drugs. Additionally, the potential antihypertensive and cardioprotective effects of several phytotherapy products have been evaluated, as these could also be a valuable therapeutic option for the prevention, improvement or treatment of hypertension and its complications. The present review includes an evaluation of the cardioprotective and antihypertensive effects of garlic, Aloe vera, green tea, Ginkgo biloba, berberine, ginseng, Nigella sativa, Apium graveolens, thyme, cinnamon and ginger, and their possible interactions with antihypertensive drugs. A literature search was undertaken via the PubMed, Google Scholar, Embase and Cochrane databases. Research articles, systematic reviews and meta-analyses published between 2010 and 2023, in the English, Hungarian, and Romanian languages were selected.